<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02323750</url>
  </required_header>
  <id_info>
    <org_study_id>TransitionCHF</org_study_id>
    <nct_id>NCT02323750</nct_id>
  </id_info>
  <brief_title>TransitionCHF Systolic Dysfunction to Congestive Heart Failure Cohort Study</brief_title>
  <official_title>Systolic Dysfunction to Congestive Heart Failure Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Göttingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medical Center Goettingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Göttingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TransitionCHF aims to recruit a unique cohort of patients with asymptomatic left ventricular
      dysfunction (NYHA I) to study the progression to symptomatic (&gt;NYHA I) HF and to identify
      parameters/ biomarkers promoting and predicting the individual risk of transition. Results
      from TransitionCHF Cohort Study will inform and refine current treatment guidelines. The
      implementation of common patient data sets and biobanking standards will enable data and
      biomaterial sharing with other DZHK study groups. This study will set the standard for a
      unique DZHK heart failure database and Biobank for innovative preclinical and clinical
      trials.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>composite endpoint of hospitalization for heart failure and cardiovascular death</measure>
    <time_frame>5 Years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Systolic Dysfunction, Transition, Heart Failure, Biobank</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The DZHK TransitionCHF Cohort Study will include patients with systolic dysfunction (NYHA
        I), i.e. (1) patients without a history of HF symptoms and (2) patients who reversed from
        symptomatic HF. Patients will be recruited prospectively at the seven participating DZHK
        centres and eight external partners from the ALKK network (German Working Group of Leading
        Hospital-based Cardiologists) and university hospitals.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Asymptomatic systolic dysfunction (defined as: ejection fraction &lt; 40% by
             echocardiography or MRI; documented within the last 3 months prior to baseline visit)

          -  No history of hospitalization for heart failure (defined as hospitalisation with
             symptoms of heart failure requiring initiation of therapy with a loop diuretic or
             escalation of a pre-existing loop diuretic therapy within 48 hours after hospital
             admission)

          -  No heart failure symptoms (NYHA II, III or IV) upon inclusion

          -  6MWD ≥ 80% of reference values

          -  Written informed consent

          -  Age ≥ 18 years

        Exclusion Criteria:

          -  Symptomatic heart failure (NYHA&gt;I) at baseline visit

          -  Any significant valvular disease (&gt; 2nd degree)

          -  Severe pulmonary disease (e. g. FEV1 &lt; 70% of normal limit)

          -  Severe renal disease (GFR &lt; 15 ml/min)

          -  ejection fraction at baseline visit ≥ 50% by echocardiography or MRI

          -  Life expectancy &lt; 1 year

          -  Pericardial disease

          -  Hypertrophic cardiomyopathy

          -  Myocardial infarction within the last 3 months

          -  Planned cardiac surgical intervention within 3 months after inclusion

          -  Geographical reasons (e. g. patients living outside Germany or planning to move
             abroad)

          -  Inability to give informed consent (e. g. mental disorders)

          -  Therapy with loop diuretics (e. g. torasemide, furosemide, piretanide)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gerd Hasenfuß, Prof</last_name>
    <phone>49-551-39-20400</phone>
    <email>rfaber@med.uni-goettingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frank Edelmann, Dr</last_name>
    <phone>49-551-39-22658</phone>
    <email>fedelmann@med.uni-goettingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Goettingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Edelmann, Dr</last_name>
      <phone>49-551-39-22658</phone>
      <email>fedelmann@med.uni-goettingen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Göttingen</investigator_affiliation>
    <investigator_full_name>Gerd Hasenfus</investigator_full_name>
    <investigator_title>Prof. Dr. med. Gerd Hasenfuß</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

